Myelofibrosis
- Treat symptoms/spleen burden + disease risk
- JAK inhibitor is the main drug class for symptomatic disease
- Choice depends on anemia, platelets + prior therapy
- Transfusions/anemia-directed therapy may be needed
- Allogeneic transplant is the only curative therapy
- Monitor progression to acute leukemia
Use at a glance
- Treat symptoms/spleen burden + disease risk
Escalation / refractory disease
- JAK inhibitor is the main drug class for symptomatic disease
- Transfusions/anemia-directed therapy may be needed
- Allogeneic transplant is the only curative therapy
Choosing treatment
- Choice depends on anemia, platelets + prior therapy
Monitoring / follow-up
- Monitor progression to acute leukemia
Self-check
- What should be treated in Myelofibrosis?
symptoms/spleen burden + disease risk.
- What should be monitored during treatment of Myelofibrosis?
progression to acute leukemia.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
